ARQL poster session as reported by mh00034, who has posted here a couple of times, but is far more active on the YMB. I think it may actually be a friend of his reporting:
>>Shapiro and Hill presenting. Crowded.
Until March 26 pts with advanced solid tumors, 1-15 (!!!) previous chemotherapies.
Two cohorts: 20 pts with previous 1h weekly administration, of them most 10-140 mg/m2 and 3 with > 200mg/m2 ARQ-501. Second cohort: 6 pts with infusion regimen (not specified 1 -3h). Pharmacodynamics after 4 weeks, safety and efficacy after 8 weeks evaluated. Average 58 years, 38-73.
Evaluable patients: 12/20 in 1st group.
8/12 with antitumor activity: 1 (or 2?) PR, 6 SD, 1 with notable tumor shrinkage of 21% by week 14 (minor response).
4/6 in second group evaluable: 3 SD + 1 minor response (shrinkage 18% by wk 19). Again, not sure, if minor response patient is included in SD pts.
MTD not reached. Alltogether 1 PR, 2 MR (minor response, shrinkage), 7 SD = 62.5% tumor activity in 16 evaluable patients by RECIST criteria for response evaluation.
Hill: "very promising mono data", "phase 2 this year", " second generation in parallel, but no answer on PEG question", "prodrug approach for 2nd gen."
VERY PROMISING to me! <<
finance.messages.yahoo.com
Cheers -- and thanks to mh00034 for getting this done, Tuck |
